Series B financing round of ImmunOs Therapeutics

ImmunOs Therapeutics AG, a biotech company focused on a new class of HLA-based therapies for the treatment of cancer and autoimmune diseases announced the closing of a CHF 71 million Series B financing. The round was co-led by Samsara BioCapital, Lightspeed Venture Partners, and Gimv, with significant participation from Mission Biocapital, GL Capital, Peak6 Strategic Capital, and Fiscus Financial, as well as existing investors Pfizer Ventures, BioMed Partners, and Schroder Adveq. 

Lenz & Staehelin advised co-lead investors Samsara Biocapital and Lightspeed Venture Partners as their Swiss counsel. The team consisted of Beat Kühni, Simone Ehrsam and Tobias Weber (all Corporate/M&A), Lukas Aebi (Tax), Elena Furlanetto (Employment) and Vera Vallone (IP).